{"type":"rich","version":"1.0","title":"The BioPharm Brief: Longer-Acting, Life-Changing, and Fast-Tracked","description":"Today’s BioPharm Brief looks at a long-acting anti-VEGF therapy entering clinical trials, the first commercial use of imlifidase in Australia for kidney transplantation, and FDA Fast Track designation for a platelet-derived biologic for chronic sciatica.","author_name":"The BioPharm Brief","author_url":"https://audioboom.com/channels/5167274-the-biopharm-brief","provider_name":"Audioboom","provider_url":"https://audioboom.com","width":480,"height":95,"thumbnail_url":"https://audioboom.com/i/43798302/600x600/c","thumbnail_width":600,"thumbnail_height":600,"html":""}